Outlook Therapeutics is trading at $0.97, down -5.58%, with no new negative company-specific catalyst identified for August 6, 2026.
- Outlook Therapeutics will report third-quarter fiscal 2026 results on August 14, 2026, a routine scheduling update rather than an immediate earnings release.
- The decline contrasts with XBI’s 2.09% gain; broader market weakness and post-FDA-approval consolidation may be contributing, but causation remains unconfirmed. The FDA approval was reported July 24, 2026.